FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)

View source ↗

Summary

The FDA approved Biocon Biologics' supplemental application for OGIVRI (trastuzumab-dkst), a trastuzumab biosimilar.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OGIVRI (trastuzumab-dkst)

Snippet

SUPPL AP for OGIVRI (TRASTUZUMAB-DKST)